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O B J E C T I V E S We hypothesized that Fabry cardiomyopathy in female patients might differ
substantially from that in male patients and sought to prove this hypothesis in a large cohort consisting
of 104 patients with Fabry disease.
B A C KG ROUND Fabry cardiomyopathy in male patients is characterized by left ventricular (LV)
hypertrophy, impaired myocardial function, and subsequent progressive myocardial ﬁbrosis. In contrast,
the occurrence of these 3 cardiomyopathic hallmarks in female patients remains unknown.
METHOD S In 104 patients (58 females, age 42  16 years; 46 males, age 42  13 years) with
genetically proven Fabry disease, LV hypertrophy, regional myocardial deformation and myocardial
ﬁbrosis were assessed by standard echocardiography, strain rate imaging, and cardiac magnetic
resonance (CMR) imaging–guided late enhancement (LE).
R E S U L T S In men, end-diastolic left ventricular wall thickness (LVWT) ranged from 6 to 19.5 mm (LV
mass CMR 55 to 200 g/m2), and LE was never seen with LVWT 12 mm (LV mass 99 g/m2). In contrast
in female patients, LVWT ranged from 5 to 15.5 mm, LV mass ranged from 39 to 146 g/m2, and LE was
already detectable with an LVWT of 9 mm (LV mass 56 g/m2). When LV mass was examined in CMR, LE
was detected in 23% of the female patients without hypertrophy (n  9), whereas LE was never seen in
male patients with normal LV mass. LE was always associated with low systolic strain rate, but the
severity of impairment was independent of LVWT in female patients (lateral strain rate in patients with
LV hypertrophy with LE 0.7  0.2 s1; patients without LV hypertrophy with LE 0.8  0.2 s1; p 
0.45).
CONC L U S I O N S In contrast to male patients, the loss of myocardial function and the development
of ﬁbrosis do not necessarily require myocardial hypertrophy in female patients with Fabry disease. Thus,
in contrast to actual recommendations, initial cardiac staging and monitoring should be based on LV
hypertrophy and on replacement ﬁbrosis in female patients with Fabry disease. (J Am Coll Cardiol Img
2011;4:592–601) © 2011 by the American College of Cardiology Foundation
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593abry disease is a lysosomal storage disorder
caused by a deficiency of alpha-galactosidase A.
Linked to the X chromosome, it was consid-
ered rare in heterozygous female carriers in
the past (1). This was explained by a skewed
inactivated X chromosome (Lyon hypothesis) (2).
Nevertheless, it is now widely accepted that
heterozygous female carriers could develop severe
cardiomyopathy and other organ manifestations
(3–9). In fact, two-thirds of all patients with Fabry
disease are female. Hence, it is important to focus
on the cardiac manifestations of Fabry disease in
female patients.
Structure damage and function loss appear in the
later stages of Fabry disease and could lead to organ
failure (10). We previously showed in clinical stud-
ies that male patients commonly experience a se-
quence of loss of regional function, left ventricular
(LV) hypertrophy, and subsequent with aging,
myocardial replacement fibrosis, leading toward
end-stage disease (11–13). It has been clearly de-
termined in male patients that at least a moderate
amount of LV hypertrophy is needed for the devel-
opment of myocardial fibrosis (12,13). Only a few
female patients were included in these clinical
studies (11,12). Moreover, subtle methods of as-
sessing cardiac function with echocardiography
(strain rate) or detecting replacement fibrosis with
cardiac magnetic resonance (CMR) (late enhance-
ment [LE]) (11–19) have not been used in studies
focusing on Fabry cardiomyopathy in female pa-
tients (8,20). Up to now, there has been no estab-
lished guideline how to monitor female patients and
when (at which stage of the disease) to treat these
patients with cardiac involvement caused by Fabry
disease. A common consensus in cardiac assess-
ment is to start with enzyme replacement therapy
(ERT) when a female patient presents with Fabry
disease with the typical cardiac hypertrophy (as-
sessed by echocardiography with an end-diastolic
wall thickness of 12 mm) together with symp-
toms attributed to hypertrophic cardiomyopathy
(12,21). Moreover, the use of CMR for nonin-
vasive assessment is not recommended as a stag-
ing tool to characterize cardiac involvement in
the guidelines (21).
The aim of the present study was to systemati-
cally evaluate cardiac involvement in female patients
with Fabry disease. Thus, we compared the char-
acteristics of Fabry cardiomyopathy in a large co-
hort of heterozygous female and male patients with
standard echocardiography, strain rate imaging, and
CMR using a cross-sectional design. mM E T H O D S
Study population. Fifty-eight female (age 42  16
years, range 10 to 71 years) and 46 male patients
(age 42  13 years, range 7 to 66 years) with
genetically confirmed Fabry disease (consecutive,
without contraindications for CMR) underwent
echocardiography and CMR when they first pre-
sented at the Fabry Center Würzburg. Echocardio-
graphic and CMR analysis were conducted blinded
to the results of the corresponding technique by 2
experts in the field of echocardiography and CMR.
Echocardiographic measurements were compared
with those from a cohort of 27 controls. The
controls were recruited from local hospital staff and
their relatives. Care was taken to recruit controls
with similar ages (Fabry group 42  15 years vs.
controls 47 15 years; p 0.10) and to include the
same proportion of female volunteers as that for
patients (Fabry 56% vs. controls 52%; p 0.83). To
match controls with patients, 7 (26%) of these
controls had a history of isolated arterial
hypertension without concomitant disease
(Fabry group 26% with hypertension).
The other controls had no history of
cardiac or systemic disease. Controls had
normal body mass index (22  4 kg/m2)
nd heart rate (70  11 beats/min). A
linical investigation program was con-
ucted as described elsewhere (22). None
f the patients with Fabry disease had
eceived ERT before study entry. The
tudy conformed to the principles outlined
n the Declaration of Helsinki, and the locally
ppointed ethics committee approved the research
rotocol. Written informed consent was obtained
rom all patients or their guardians.
Standard echocardiographic measurements. Left
ventricular end-diastolic and end-systolic dimen-
sions and end-diastolic thickness of the posterior
wall and the septum were measured using anatomic
M-mode echocardiographic methods and paraster-
nal LV long-axis images (3.5 MHz, GE Vingmed
Vivid 7, Horten, Norway). Ejection fraction was
calculated using the modified Simpson method.
Blood pool pulsed Doppler of the mitral valve
inflow was used to determine the ratio of early to
late diastolic flow velocity and the deceleration
time.
Assessment of hypertrophy. Left ventricular wall
hickness (LVWT) was defined as the higher end-
iastolic value of the posterior or the septal wall,
A B B
A N D
ERT
therap
FD
LE l
LV
LVWT
wall theasured with anatomic M-mode (this wasR E V I A T I O N S
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594sary because of the known thinning of the posterior
wall in male patients having end-stage disease) (23).
Following guidelines and publications for diagnos-
ing and monitoring Fabry disease, LV hypertrophy
was defined as a diastolic LVWT greater than 12
mm (12,21). However, the gold standard for myo-
cardial mass is CMR. Thus, we also calculated
myocardial mass by cine CMR indexed to body
surface area (BSA) and took age and gender into
account as recommended in recently published
reports (24–26). Analysis of LV mass was per-
formed by manual segmentation of the endocardial
and epicardial borders of the end-diastolic and
end-systolic frames as previously described (27).
Strain rate imaging. Real-time 2-dimensional color
oppler myocardial imaging data were recorded
rom the interventricular septum and the LV lateral
all using standard apical 4-chamber views to
valuate longitudinal function (3.5 MHz, GE
ingmed Vivid 7). For assessment of radial func-
ion of the posterior wall, parasternal long-axis
iews were used. Data from color Doppler myocar-
Table 1. Characteristics of Female and Male Patients With Fabr
Female Controls
(n  14)
Age, yrs 49 17
BMI, kg/m2 21.7 3.4
HR, beats/min 69 11
Systolic BP, mm Hg 125 10
Diastolic BP, mm Hg 76 6
Arterial hypertension* 3 (21)
Proteinuria N/A
GFR, ml/min/1.73 m2 99 16
Hemoglobin, g/dl 13.7 0.7
Data are presented as mean  SD or n (%). *Arterial hypertension deﬁned as sys
‡p  0.05 versus female patients. §p  0.05 versus male controls.
BMI  body mass index; BP  blood pressure; GFR  glomerular ﬁltration ra
Table 2. Echocardiographic Parameters of Female and Male Pat
Female Controls
(n  14)
Fem
(
Radial SR, s1 2.5 0.6
Septal SR, s1 –1.3 0.3 
Lateral SR, s1 –1.3 0.2 
LVWT, mm 8.8 1.7
LVEDD, mm 47 6
LVESD, mm 31 5
EF, % 64 6
E/A 1.2 0.5
DT, ms 205 62
Data are presented as mean  SD. *p  0.05 versus female controls. †p  0.0
DT  deceleration time; E/A  ratio of early to late diastolic ﬂow velocity; E
diameter; LVESD  left ventricular end-systolic diameter; LVWT  left ventricular wial imaging were analyzed using dedicated soft-
are (Echopac, GE Ultrasound). Radial strain rate
urves of the mid-basal posterior wall and longitu-
inal strain rate curves of the mid-apical septum
nd basal-mid lateral wall were extracted, as recom-
ended in recent reports (14,16,28). Peak systolic
train rate (SRSYS) was derived from the resulting
strain rate curves.
Assessment of ﬁbrosis. CMR with injection of
adopentetate dimeglumine 0.2 mmol/kg (Magn-
vist, Schering AG, Berlin, Germany) was carried
ut in all 104 patients on a 1.5-T scanner (Magne-
om VISION, Siemens Medical Systems, Erlangen,
ermany). The LE technique (8-mm slice thick-
ess, breath hold, short heart axis) was applied to
etect changes of tissue integrity in the LV myo-
ardium. Images were acquired using an inversion
ecovery sequence (field of view 240  320 mm2,
atrix 165  256, repetition time 7.5 ms, echo
time 3.4 ms, flip angle 25°, inversion time deter-
mined individually). Short-axis views at the basal,
mid, and apical segments, covering the entire ven-
sease and Controls
Female Patients
(n  58)
Male Controls
(n  13)
Male Patients
(n  46)
42 16 46 12 42 13
23.5 4.8 22.6 3.7 22.2 3.5
65 14 71 11 65 13
123 16 121 9 126 19
77 18 78 8 82 10
10 (17) 4 (31) 16 (35)
24 (41%) N/A 28 (61%)
103 29 95 19 69 46†‡§
13.1 1.2 15.8 1†‡ 13.7 1.3§
BP 140 mm Hg or diastolic BP 90 mm Hg. †p  0.05 versus female controls.
R  heart rate; N/A  not available.
s With Fabry Disease and Controls
atients
58)
Male Controls
(n  13)
Male Patients
(n  46)
 1.1 3.0 0.4 2.8 1.2
 0.4 –1.2 0.3 1.3 0.5
 0.4 –1.3 0.2 1.1 0.5
 2.6 9.5 1.8 13.5 2.6*†‡
 5 50 6† 50 6†
 6 32 4 32 5
 6 64 4 62 6
 0.4 1.2 0.5 1.3 0.4
 50 225 62 219 64
rsus female patients. ‡p  0.05 versus male controls.
ejection fraction; LV  left ventricular; LVEDD  left ventricular end-diastolicy Di
tolicient
ale P
n 
2.9
1.5
1.2
9.8
46
32
64
1.4
192
5 ve
F all thickness; SR  strain rate.
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595tricle, were used for the quantitative assessment of
LE (if present) by manual tracing of the LE area.
Using this LE technique, every LV segment, using
the standard 17-segment model, was evaluated for
the occurrence of myocardial replacement fibrosis.
A ratio of LE to complete LV cardiac mass was
calculated.
Subgroup analysis. For advanced analysis, the pa-
ients of each sex were divided in 2 groups: the ones
ith hypertrophy and those without. Thereafter,
hese groups were further divided into fibrosis and
onfibrosis groups (4 groups for each sex). This was
one for echocardiographic and CMR hypertrophy
ssessments separately.
Data analysis. Data are presented as mean  SD or
s absolute patient numbers. Differences between
he groups were tested using an unpaired t test or
nalysis of variance (1-way or 2-way) or multivari-
te analysis of variance with the Duncan post hoc
est as indicated. Fisher exact test was used for
ategorical variables. A value of p  0.05 was
considered statistically significant. Statistical tests
were not performed in 2 subgroups with echocar-
diographic LV hypertrophy assessment (female pa-
Figure 1. Distribution of LE Depending on LVWT in Female Pati
Each bar symbolizes a single patient. Patients showing late enhanc
their left ventricular wall thickness (LVWT), the y-axis displaying the
toward LV hypertrophy. Note that some female patients were alrea
diac magnetic resonance.
Figure 2. Distribution of LE Depending on LVWT in Male Patien
Each bar symbolizes a single patient. Patients showing LE are green
displaying the amount of end-diastolic LVWT. The pink line indicat
only LE positive if they have an LVWT 12 mm and that male patie
female patients (Fig. 1). Abbreviations as in Figure 1.tients with hypertrophy but without fibrosis and
male patients without hypertrophy but with fibro-
sis) because of low patient numbers. Statistica
version 8.0 (StatSoft GmbH, Hamburg, Germany)
was used.
R E S U L T S
Fabry cohort. Between October 2001 and October
008, a total of 104 consecutive patients (58 females
nd 46 males) with genetically proven Fabry disease
ere included in this study. The characteristics of
he patients with Fabry disease and controls are
iven in Table 1. Patients and controls are subdi-
ided by sex. Ten female and 16 male patients had
history of mild hypertension; all were normoten-
ive at study entry under antihypertensive drug
herapy.
Echocardiography. The echocardiographic parame-
ers of patients with Fabry disease and controls are
iven in Table 2. Patients and controls are subdi-
ided by sex. The ejection fraction and diastolic
arameters did not differ between female and male
atients and respective sex-matched controls. The
s With Fabry Disease
nt (LE) are green bars. The patients are shown in the order of
ount of end-diastolic LVWT. The pink line indicates the border
E positive (green bars) without being hypertrophic. CMR  car-
ith Fabry Disease
rs. The patients are shown in the order of their LVWT, the y-axis
e border toward LV hypertrophy. Note that male patients are
develop a larger amount of LV hypertrophy compared withent
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dy Lts W
ba
es th
nts
a
C
t
s
w
I
b
s
e
p
t
t
CMR  cardiac magnetic
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 4 , N O . 6 , 2 0 1 1
J U N E 2 0 1 1 : 5 9 2 – 6 0 1
Niemann et al.
Cardiomyopathy in Female Patients With Fabry Disease
596LV diameters were in the normal range in all
groups.
WALL THICKNESS AND MASS. The LVWT was sig-
nificantly higher in male patients with Fabry disease
than in the 3 other groups (male controls, female
controls, female patients), who showed similar
LVWT (Table 2). In the 58 female patients,
LVWT ranged from 5 to 15.5 mm (LV mass CMR
39 to 146 g/m2). In the male patients (n  46),
LVWT ranged from 6 to 19.5 mm (LV mass CMR
55 to 200 g/m2). According to Fabry guideline
criteria, 48 female patients showed no LV hyper-
trophy and only 10 female patients had LV hyper-
trophy (Fig. 1). In contrast, a large number of male
patients had LV hypertrophy (n  30), and only 16
Figure 3. Distribution of LE Regarding LV Mass by CMR Indexed
Male patients are displayed on the left and female patients on the
indexed to body surface area according to the hypertrophy criteria
adolescents, respectively). The patients with 1 LE-positive segmen
none of the male patients with normal LV-mass showed LE, wherea
Abbreviations as in Figure 1.
cteristics of Female Patients With Fabry Disease According to Fib
c Wall Thickness)
No Hypertrophy/No Fibrosis
(n  38)
No Hypertrophy/Fibrosis 
(n  10)
3.5 0.9 1.9 0.6*
1.5 0.4 1.4 0.3
1.4 0.3 0.8 0.2*
8.5 1.8 10.9 1.0*
60 12 64 5
an  SD. *p  0.05 versus no hypertrophy/no ﬁbrosis group. †p  0.05 versus n
resonance; other abbreviations as in Table 2.male patients showed no LV hypertrophy (p 0.001)
(Fig. 2).
Fibrosis. LE was detected in 33% of the female (n 19)
nd 48% of the male (n  22; p  0.16) patients. In
MR LE in female patients consistently occurred in
he basal posterolateral wall (n 19). The septal basal
egment showed additional LE in 2 female patients,
hereas fibrosis was not found in any other segments.
n male patients, 22 LE segments were found in the
asal posterolateral wall, 8 in anterior septal basal
egments, and 1 in the mid septum. When the
xtension of LE within the wall was examined, 28
atients showed a localized mid myocardial LE in the
ypical location: lateral-basal. Two patients had addi-
ional endocardial fibrosis lateral-basal, and 1 patient
Body Surface Area
t. The patients were classiﬁed using LV mass assessed by CMR
gested by Alfakih et al. (25) and Cain et al. (26) (for adults and
ercentage) are shown in each group by shaded bars. Note that
e-fourth of the female patients with normal LV mass showed LE.
is (by CMR) and LV Hypertrophy
Hypertrophy /No Fibrosis
(n  1)
Hypertrophy /Fibrosis 
(n  9)
2.7 1.9 0.6*
1.4 1.4 0.3
1.9 0.7 0.2*
12.5 14.1 1.0*†
91.0 100 25*†
pertrophy/ﬁbrosis  group.to
righ
sug
t (p
s onTable 3. Group Chara ros
(by Echocardiographi
Radial SR, s1
Septal SR, s1
Lateral SR, s1
LVWT, mm
LV mass CMR, g/m2
Data are presented as me o hy
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597showed epicardial fibrosis. In 10 patients, transmural
LE was observed.
In female patients, LE-positive segments were
already detectable at an LVWT of 9 mm (female
patient with lowest LV mass CMR and LE: 56
g/m2; limit for hypertrophy in this patient 77
g/m2), and 10 female patients without hypertrophy
already presented LE-positive segments (Fig. 1). In
contrast, LE was not found in male patients with
LVWT 12 mm (male patient with lowest LV
mass and LE: 99 g/m2) (Fig. 2). Only 1 female
atient with echocardiographic hypertrophy (LVWT
2.5 mm) showed no fibrosis, whereas 12 male
atients (40%) had LV hypertrophy and did not
resent fibrotic segments. Fibrosis was detected in
ll female patients with LVWT 13 mm and in all
ale patients with LVWT 16 mm (p  0.04 for
isher exact test between male and female patients
VWT 13 mm) (Figs. 1 and 2).
In the 10 female patients without LV hypertrophy
ut with fibrosis, no wall motion abnormality was
etected with echocardiography. Even when these 10
atients were reanalyzed with the CMR results (hav-
ng fibrosis), no wall motion abnormality could be
een in echocardiography. None of the 10 patients
ithout hypertrophy but with fibrosis had complained
bout heart failure symptoms in the past, and they
ere referred to our center because of family screening
n  7) and neuropathic pain (n  3). Nevertheless,
hese patients only reached 75  11% of their calcu-
Table 4. Group Characteristics of Male Patients With Fabry Dise
(by Echocardiographic Wall Thickness)
No Hypertrophy/No Fibrosis
(n  12)
No H
Radial SR, s1 3.9 1.2
Septal SR, s1 1.4 0.4
Lateral SR, s1 1.5 0.7
LVWT, mm 10.8 2.0
LV mass CMR, g/m2 78 15
Data are presented as mean  SD. *p  0.05 versus no hypertrophy/no ﬁbrosi
Abbreviations as in Tables 2 and 3.
Table 5. Group Characteristics of Female Patients With Fabry D
No Hypertrophy/No Fibrosis
(n  35)
No H
Radial SR, s1 3.6 0.9
Septal SR, s1 1.5 0.4
Lateral SR, s1 1.4 0.4
LVWT, mm 8.4 1.8
LV mass CMR, g/m2 56 8
Data are presented as mean  SD. *p  0.05 versus no hypertrophy/no ﬁbrosi
Abbreviations as in Tables 2 and 3.ated target workload when performing a bicycle stress
est, whereas the female patients without LV hyper-
rophy and without LV fibrosis reached their target
ith 109  24% power (p  0.002).
When hypertrophy was re-evaluated by quantifi-
ation of LV mass with CMR (indexed to BSA), 9
f 10 female patients (with LE-positive segments
nd initially classified by echocardiographic wall
hickness as LV nonhypertrophic) showed normal
V mass (Fig. 3). Only 1 of these female patients
howed an LV mass above the limit (81 g/m2). In
oncordance with the assessment of LVWT, LE
as present in 23% of the female patients with
ormal LV mass (indexed to BSA, with consider-
tion of age and sex); in contrast, no LE was seen in
ale patients with normal LV mass (Fig. 3).
The mean extent of myocardial fibrosis was 2.4
.8% (range 0.2% to 21.4%) of the complete myo-
ardium. In female patients, the extent of myocar-
ial fibrosis was 1.8 1.7%; in male patients, it was
.8  4.8% (p  0.45). There was no difference in
the amount of LE in female patients with or
without hypertrophy: 2.4  0.7% versus 2.2 
2.2%, respectively (p  0.32).
Regional myocardial function. SRSYS values were
imilar among all groups (female and male patients
nd female and male controls), as presented in
able 2. Echocardiographic subgroup analysis
Tables 3 and 4) showed that the female patients
ithout hypertrophy and without fibrosis (n  38)
According to Fibrosis (by CMR) and LV Hypertrophy
rtrophy/Fibrosis 
(n  4)
Hypertrophy /No Fibrosis
(n  12)
Hyper
2.6 0.8 2.8 0.7
1.8 0.5* 1.4 0.3†
0.9 0.4* 1.1 0.3
12.0 0 13.6 1.0*
81 11 91 13
up. †p  0.05 versus no hypertrophy/ﬁbrosis  group. ‡p  0.05 versus hypertro
se According to Fibrosis and LV Hypertrophy (Both by CMR)
rtrophy/Fibrosis 
(n  9)
Hypertrophy /No Fibrosis
(n  4)
Hyper
1.9 0.6* 2.8 0.8†
1.4 0.4 1.3 0.2
0.8 0.2* 1.1 0.1
10.9 1.1* 11.3 0.5*
62 4 82 9*†
up. †p  0.05 versus no hypertrophy/ﬁbrosis  group. ‡p  0.05 versus hypertroase
ype trophy /Fibrosis 
(n  18)
2.1 1.0*
1.2 0.6†
0.8 0.4*‡
15.5 2.2*†
122 49*†‡
s gro phy /no ﬁbrosis group.isea
ype trophy /Fibrosis 
(n  10)
2.0 0.6*
1.4 0.3
0.7 0.2*‡
14.1 1.2*†‡
98 24*†‡
s gro phy /no ﬁbrosis group.
pAbbreviations as in Table
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598had a significantly higher regional myocardial func-
tion than the 2 female groups with fibrosis. There
was no difference in myocardial function in these 2
groups with fibrosis, although the LVWT and LV
CMR mass were significantly different (Table 3).
The comparison of the LV hypertrophic male
patients with (n 18) and without fibrosis (n 12)
showed that the group with fibrosis had lower radial
and longitudinal SRSYS values (Table 4). In male
atients, the highest SRSYS values were found in
the patient group without both LV hypertrophy
and fibrosis. Myocardial function was similar in
male and female subgroups with comparable LE
and hypertrophy conditions (Tables 3 and 4).
Tables 5 and 6 provide the same subgroup anal-
ysis presented in Tables 3 and 4 but with hyper-
trophy assessed by CMR (LV mass) instead of
echocardiography. In general, the same findings
as in the echocardiographic subanalysis could be
detected. The data in Table 5 confirm the echo-
cardiographic finding that female patients with-
out hypertrophy (normal LV mass in CMR)
show LE.
Age and morphological changes. The distribution of
LVWT and LE in relation to age is shown in
Figures 4 (female patients) and 5 (male patients).
The youngest female patient with LE was 36 years
Figure 4. Distribution of LE Depending on Age in Female Patien
Each bar symbolizes a single patient. Patients showing LE are green b
the amount of end-diastolic LVWT. The pink line indicates the border
cteristics of Male Patients With Fabry Disease According to Fibro
No Hypertrophy/No Fibrosis
(n  14)
No Hypertrophy/Fibrosis 
(n  0)
3.4 1.3 —
1.3 0.4 —
1.3 0.4 —
11.1 2.2 —
74 10 —
an  SD. *p  0.05 versus no hypertrophy/no ﬁbrosis group. †p  0.05 versus h
s 2 and 3.were nonhypertrophic already showed LE and some older patients did notof age, and the youngest male patient with LE was
23 years of age. Even a 20-year-old male patient
showed hypertrophy, whereas hypertrophy was not
seen in female patients before the age of 46 years.
Thus, in our female cohort, LE occurred earlier
than LV hypertrophy. LE was not detected in 4 of
13 female patients (31%) and 2 of 12 male patients
(17%) older than 50 years (p  0.65).
D I S C U S S I O N
This study is the first systematic single-center inves-
tigation using subtle methods like strain rate imaging
and CMR to highlight cardiomyopathy in female
patients with Fabry disease. With a cross-sectional
study design in a large Fabry cohort, the main results
obtained were: 1) in 34% of the complete Fabry
female cohort, signs of cardiomyopathy (hypertrophy
or fibrosis) were found; 2) in contrast to male patients,
there was no fixed linkage of hypertrophy and fibrosis
in female patients with Fabry disease (e.g., female
patients can develop some replacement fibrosis with-
out being hypertrophic); and 3) 50% of the female
patients with signs of relevant cardiomyopathy would
not have been detected by the guideline-proposed
standard echocardiographic and LV hypertrophy as-
sessment.
ith Fabry Disease
The patients are sorted in the order of their age. The y-axis displays
ard LV hypertrophy. Note that some younger female patients who
and LV Hypertrophy (Both by CMR)
Hypertrophy /No Fibrosis
(n  11)
Hypertrophy /Fibrosis 
(n  21)
3.2 0.9 2.2 1.0*
1.4 0.2 1.3 0.6
1.3 0.7 0.8 0.4*†
13.5 1.1* 15.4 2.9*
98 8* 125 36*†
trophy /no ﬁbrosis group.ts W
ars.
towTable 6. Group Chara sis
Radial SR, s1
Septal SR, s1
Lateral SR, s1
LVWT, mm
LV mass CMR, g/m2
Data are presented as me ypershow cardiac involvement at all. Abbreviations as in Figure 1.
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599Female Fabry cardiomyopathy. From previous stud-
es, it is known that the morphological hallmarks of
abry cardiomyopathy are LV hypertrophy and
eplacement fibrosis, which are both consistent with
he finding of reduced regional LV function. In
ale patients, the LV starts to hypertrophy during
dolescence; this is accompanied by reduced longi-
udinal function (12,13,17,18). The hypertrophy in
hese male patients progresses quite fast and finally
eads to replacement fibrosis (12–14). Both the
ypical Fabry cardiomyopathy findings and the de-
cribed temporal sequence were also evident in our
ale cohort. In contrast, the fixed linkage of hy-
ertrophy and fibrosis seemed to be not applicable
or female patients with Fabry disease, although in
eneral the same hallmarks (i.e., hypertrophy, re-
uced regional myocardial function, and replace-
ent fibrosis) can be detected in the hearts of most
emale patients with Fabry cardiomyopathy. Thus,
t seems that in our cohort, the progression toward
evere hypertrophy in female patients was pro-
onged because of the residual activity of alpha-
alactosidase A (caused by the random inactivation
f the mutated or nonmutated X chromosome).
his is in concordance with previous studies done
y Goldman et al. (29) and Linhart et al. (30),
howing that LV hypertrophy is more common in
ale than in female patients. However, despite the
elayed development of hypertrophy, fibrosis seems
o progress continuously. Therefore, as shown in
he current study, replacement fibrosis can already
e present in the female heart with Fabry disease at
nonhypertrophic disease stage (Fig. 6). In addi-
ion, it could be shown that in all hearts that
rogress toward LV hypertrophy, replacement fi-
rosis is an integral component of Fabry cardiomy-
pathy in female patients. As expected, regional LV
Figure 5. Distribution of LE Depending on Age in Male Patients
Each bar symbolizes a single patient. Patients showing LE are green
displays the amount of end-diastolic LVWT. The pink line indicates
ing to age in male patients was earlier than that in female patientsunction was significantly reduced in the fibroticegments. Interestingly, this reduction of regional
ongitudinal function was independent of the de-
ree of hypertrophy. This might lead to the specu-
ation that in general regional myocardial function
n Fabry cardiomyopathy could be more related to
issue fibrosis and less to hypertrophy. Furthermore,
ome female patients with Fabry disease obviously
ave a compensatory mechanism that protects the
eart even in advanced age from developing typical
ardiomyopathy. However, it is impossible to de-
ide whether the differences between male and
emale patients might be due to an altered temporal
equence of cardiomyopathy in female patients (a
th Fabry Disease
rs. The patients are sorted in the order of their age. The y-axis
border toward LV hypertrophy. Note that the onset of LE accord-
breviations as in Figure 1.
Figure 6. Echocardiographic and CMR Images of a Female Patie
Without LV Hypertrophy but With LE
(A) Short-axis echocardiographic view. (B) 4-chamber echocardiogra
view. The LV cavity is marked with LV. The images clearly show tha
hypertrophy is present. (C) Short-axis view of the same patient usin
technique by CMR. (D) 4-chamber CMR view. The arrows indicate LWi
ba
thent
phic
t no LV
g the LE
E in thelateral wall. Abbreviations as in Figures 1 and 2.
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600“speculative” model is given in Fig. 7) or due to
phenotypical variability.
Clinical implications. These findings might have im-
lications for the initial staging and cardiac monitor-
ng of female patients with Fabry disease. In general,
he progression toward cardiomyopathy is monitored
y echocardiographic assessment of end-diastolic
VWT; in contrast, CMR and strain rate imaging is
ften proposed to be optional (21). Thus, by this
pproach, one-half of the Fabry cardiomyopathy in
ur female cohort would have not been detected. It
as shown in a previous report that strain rate imaging
elps to identify male patients with subclinical Fabry
ardiomyopathy presenting without LV hypertrophy
18). However, the findings of our present study
mphasize that especially in female patients, CMR
e 7. Cardiomyopathy Disease Progression in Male and Female
nts With Fabry Disease
allmarks of Fabry cardiomyopathy (increasing wall thickness, regional
onal abnormalities, and replacement ﬁbrosis) are used to describe
isease progression during aging of both sexes. (A) In male patients,
starts to hypertrophy during adolescence, and this is accompanied
uced longitudinal function. During aging, these 2 features lead to
ement ﬁbrosis. (B) Cardiomyopathy disease progression in female
ts is different. In contrast to male patients, the 3 hallmarks cannot
scribed as a temporal sequence toward ﬁbrosis. In contrast, it is
a vicious circle: the progression toward hypertrophy is prolonged,
as the development of ﬁbrosis and regional functional abnormalities
esses simultaneously. Abbreviations as in Figure 1.ith LE imaging is necessary to evaluate cardiomy-
pathy. This is emphasized by the fact that even with
he knowledge of LE in none of the female patients
ithout LV hypertrophy but with LE, a wall motion
bnormality could be identified with echocardiography.
n addition, as known from previous work, only patients
ithout cardiac fibrosis will profit in the long term from
RT (12). Thus, the assessment of fibrosis in female
abry patients might guide therapy initiation and might
ave implications for treatment expectations.
In patients contraindicated for CMR, strain rate
maging might be of advantage for the functional
ssessment of cardiomyopathy-related fibrosis (31).
By genetic definition, two-thirds of all Fabry pa-
ients are female; therefore, cardiologists have to be
ware of characteristic Fabry cardiomyopathy in fe-
ale patients. This is an upcoming challenge because
lot of uncharacterized and untreated female patients
ave been found in screening studies and by subse-
uent family screening in the last years.
Study limitations. In principle, longitudinal data are
ecessary to describe the temporal sequence of cardio-
yopathy progression. However, the large cohort of
atients with a standardized evaluation should be
ufficient to allow an approximate description of the
emporal sequence of the cardiac disease. We did not
im to clarify disease progression in female patients
ith this study but wanted to emphasize that in
emale patients, the diagnostic approach toward car-
iomyopathy has to include CMR with LE imaging.
hus, the aim was to emphasize the importance of
oninvasive assessment of myocardial fibrosis in fe-
ale patients with Fabry disease.
For ethical reasons, we did not undertake myo-
ardial biopsies in the patients to determine the
nderlying histological morphology.
C O N C L U S I O N S
Fabry cardiomyopathy in female patients differs from
that in male patients. Female patients can develop fibro-
sis without showing LV hypertrophy. Therefore, staging
and monitoring female patients with Fabry disease
should routinely include the assessment of replacement
fibrosis. Moreover, new treatment indications for female
patients with Fabry disease seem to be needed.
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